Anna Squadrilli

738 total citations
17 papers, 560 citations indexed

About

Anna Squadrilli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Anna Squadrilli has authored 17 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Anna Squadrilli's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Anna Squadrilli is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Anna Squadrilli collaborates with scholars based in Italy, France and United States. Anna Squadrilli's co-authors include Marcello Tiseo, Roberta Minari, Paola Bordi, Lorena Bottarelli, Letizia Gnetti, Melissa Bersanelli, Sebastiano Buti, Cecilia Bozzetti, Costanza Lagrasta and Marco Mor and has published in prestigious journals such as Annals of Oncology, Cancers and Journal of Thoracic Oncology.

In The Last Decade

Anna Squadrilli

17 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Squadrilli Italy	11	394	392	220	127	61	17	560
Elaine Shum United States	13	348 0.9×	388 1.0×	176 0.8×	69 0.5×	78 1.3×	52	586
C. Zhou China	9	551 1.4×	449 1.1×	202 0.9×	153 1.2×	41 0.7×	50	660
Tzu‐Hsiu Tsai Taiwan	13	471 1.2×	372 0.9×	183 0.8×	178 1.4×	37 0.6×	17	611
Christie J. Lau United States	10	288 0.7×	264 0.7×	148 0.7×	159 1.3×	65 1.1×	14	503
Luis Paz Ares Spain	7	262 0.7×	462 1.2×	188 0.9×	99 0.8×	154 2.5×	10	665
Bin-Chi Liao Taiwan	15	561 1.4×	553 1.4×	217 1.0×	118 0.9×	48 0.8×	36	791
Hidejiro Torigoe Japan	13	186 0.5×	216 0.6×	242 1.1×	108 0.9×	35 0.6×	28	450
Antonio Russo Italy	8	270 0.7×	296 0.8×	114 0.5×	155 1.2×	36 0.6×	14	428
Bin-Chao Wang China	9	426 1.1×	386 1.0×	133 0.6×	172 1.4×	31 0.5×	21	560
Nobuya Mino Japan	8	274 0.7×	312 0.8×	171 0.8×	104 0.8×	75 1.2×	12	508

Countries citing papers authored by Anna Squadrilli

Since Specialization

Citations

This map shows the geographic impact of Anna Squadrilli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Squadrilli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Squadrilli more than expected).

Fields of papers citing papers by Anna Squadrilli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Squadrilli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Squadrilli. The network helps show where Anna Squadrilli may publish in the future.

Co-authorship network of co-authors of Anna Squadrilli

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Squadrilli. A scholar is included among the top collaborators of Anna Squadrilli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Squadrilli. Anna Squadrilli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Minari, Roberta, Francesco Bonatti, Giulia Mazzaschi, et al.. (2021). PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Tumori Journal. 108(1). 47–55. 9 indexed citations

Tommasi, Chiara, Benedetta Pellegrino, Daniela Boggiani, et al.. (2021). Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers. Frontiers in Oncology. 11. 700853–700853. 8 indexed citations

Minari, Roberta, Letizia Gnetti, Paola Bordi, et al.. (2021). Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature. Cancers. 13(21). 5403–5403. 9 indexed citations

Mazzaschi, Giulia, Roberta Minari, Alessandra Zecca, et al.. (2020). Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. Lung Cancer. 148. 1–11. 82 indexed citations

Minari, Roberta, Letizia Gnetti, Costanza Annamaria Lagrasta, et al.. (2020). Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report. Translational Lung Cancer Research. 9(3). 787–792. 13 indexed citations

Bozzetti, Cecilia, Anna Squadrilli, Rita Nizzoli, et al.. (2020). Optimizing PD-L1 Evaluation on Cytological Samples from Advanced Non-Small-Cell Lung Cancer. Immunotherapy. 12(3). 183–193. 6 indexed citations

Dall’Olio, Filippo Gustavo, Francesca Abbati, Francesco Facchinetti, et al.. (2020). CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology. 12. 3863568034–3863568034. 37 indexed citations

Monica, Silvia La, Roberta Minari, Daniele Cretella, et al.. (2019). Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. Journal of Experimental & Clinical Cancer Research. 38(1). 222–222. 54 indexed citations

Bordi, Paola, Marzia Del Re, Roberta Minari, et al.. (2019). From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Lung Cancer. 131. 78–85. 42 indexed citations

10.

Cinausero, M., Noemi Laprovitera, Giovanna De Maglio, et al.. (2019). KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology. 11. 3862500580–3862500580. 32 indexed citations

11.

Negri, Francesca, Cecilia Bozzetti, Giuseppe Pedrazzi, et al.. (2019). High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer. Oncology Reports. 42(6). 2750–2758. 12 indexed citations

12.

Cinausero, M., Noemi Laprovitera, Giovanna De Maglio, et al.. (2019). KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC. Annals of Oncology. 30. ii55–ii56. 8 indexed citations

13.

Minari, Roberta, Paola Bordi, Silvia La Monica, et al.. (2018). Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 13(6). e89–e91. 33 indexed citations

14.

Facchinetti, Francesco, Michele Veneziani, Sebastiano Buti, et al.. (2018). Clinical and Hematologic Parameters Address the Outcomes of Non-Small-Cell Lung Cancer Patients Treated With Nivolumab. Immunotherapy. 10(8). 681–694. 28 indexed citations

15.

Negri, Francesca, Cecilia Bozzetti, Anna Squadrilli, et al.. (2017). Fingerprint Change: Not Visible, But Tangible. Journal of Forensic Sciences. 62(5). 1372–1373. 4 indexed citations

16.

Bersanelli, Melissa, Roberta Minari, Paola Bordi, et al.. (2016). L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC. Journal of Thoracic Oncology. 11(10). e121–e123. 143 indexed citations

17.

Bozzetti, Cecilia, Rita Nizzoli, Marcello Tiseo, et al.. (2015). ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non‐small cell lung cancer patients. Diagnostic Cytopathology. 43(11). 941–946. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact